Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label study of TSL-1502 versus physician's choice chemotherapy in germline BRCA-mutated HER2-negative advanced breast cancer
CTR20220461Phase 2Active
- Sponsor
- Tasly Diyi Pharmaceutical
- Start
- Aug 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TSL-1502 in breast cancer, sponsored by Tasly Diyi Pharmaceutical. Started Aug 2022; status: active.
02
Drugs
TSL-1502
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20220461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220461.